Zhaoke Ophthalmology

Commercial stage biotech company dedicated to the R&D, manufacturing and commercialization of therapies that address significant unmet medical needs in ophthalmology. Zhaoke has a comprehensive drug portfolio of innovative and generic treatments covering 6 major eye diseases across both the front and back of the eye including DED, myopia, presbyopia, wet AMD, DME and glaucoma. Zhaoke launched a medical-device grade eyepatch for dry eye in late 2022, and Bimatoprost Timolol Eye Drop for treatment of glaucoma in February 2023.